Monitor the Q3 2026 closing timeline and regulatory/ shareholder approval process. The acquisition positions AbbVie for long-term growth in dermatology and respiratory, but near-term EPS dilution and debt-funded financing are headwinds. Watch for Phase 3 data readouts for zumilokibart in atopic dermatitis, expected to start in 2H 2026.
Price Chart
Executive Summary
AbbVie announced the acquisition of Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion in equity value. The deal adds Apogee's late-stage immunology pipeline, led by zumilokibart (APG777) for atopic dermatitis and the dual IL-13/TSLP combination APG273 for asthma, deepening AbbVie's dermatology and respiratory presence. The acquisition is expected to close in Q3 2026 and be accretive to adjusted diluted EPS beginning in 2032.
Key Facts
- Total equity value of approximately $10.9 billion.
- Purchase price of $135.11 per share in cash.
- Premium of approximately 49% to Apogee's closing price on June 18, 2026.
- Transaction expected to close in Q3 2026.
- Expected to be accretive to AbbVie's adjusted diluted EPS beginning in 2032.
- Expected to negatively impact adjusted diluted EPS by approximately $0.14 in 2026 (partial year) and approximately $0.46 in 2027.
- Will fund the transaction with debt; expects to maintain A2/A- credit rating and achieve net leverage ratio of 2x within 2-3 years of closing.
- Apogee's lead asset zumilokibart (APG777) is a late-stage half-life extended anti-IL13 monoclonal antibody for atopic dermatitis, with Phase 2 data showing best-in-category efficacy and Q12W-Q24W dosing.
- APG273 (zumilokibart + APG333, anti-TSLP) is in development for asthma and COPD.
- Boards of both companies unanimously approved the transaction.
- Fairmount Funds Management LLC and Venrock Associates have entered into voting agreements in support of the transaction.
- Financial advisors: Morgan Stanley & Co. LLC (AbbVie), Jefferies LLC and Goldman Sachs & Co. LLC (Apogee).
Financial Impact
Approximately $10.9 billion total equity value, funded with debt; near-term EPS dilution of ~$0.14 in 2026 and ~$0.46 in 2027, with accretion expected from 2032.
Risk Factors
- Regulatory or Apogee shareholder approval delays could push closing beyond Q3 2026.
- Clinical trial failure or adverse safety signal for zumilokibart or APG273 could impair deal value.
- Integration challenges and competition from existing AD and asthma therapies (Dupixent, Ebglyss, tezepelumab).
- Higher-than-expected debt load or credit rating downgrade could impact financial flexibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-076067 |
| Document: tm2618365d1_8k.htm | 0001104659-26-076067 |
| Document: tm2618365d1_ex99-2.htm | 0001104659-26-076067 |
| Document: 0001104659-26-076067-index-headers.html | 0001104659-26-076067 |
| Document: 0001104659-26-076067-index.html | 0001104659-26-076067 |
| Document: 0001104659-26-076067.txt | 0001104659-26-076067 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $262.82 (+0.40%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $262.82 (+1.00%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $262.82 (+7.77%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $262.82 (+7.23%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $262.82 (+7.23%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $262.82 (+4.73%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $262.82 (+2.30%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $262.82 (+14.26%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $262.82 (+25.50%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $262.82 (+28.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access